Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates.
Journal
Paediatric drugs
ISSN: 1179-2019
Titre abrégé: Paediatr Drugs
Pays: Switzerland
ID NLM: 100883685
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
accepted:
20
02
2023
medline:
14
4
2023
pubmed:
22
3
2023
entrez:
21
3
2023
Statut:
ppublish
Résumé
Amikacin is preferred in treating Gram-negative infections in neonates and it has a narrow therapeutic window. The population pharmacokinetic modeling approach can aid in designing optimal dosage regimens for amikacin in neonates. In this study, we attempted to identify the suitable population pharmacokinetic model from the published reports for the study population from an Indian setting. Published population pharmacokinetic studies for amikacin in neonates were identified. Data on structural models and typical pharmacokinetic parameters were extracted from the studies. For the clinical study, neonates who met the inclusion criteria were enrolled in the study from the NICU, Kasturba Medical College, Manipal, during Jan 2020 to March 2022. Drug concentrations were estimated, and demographic and clinical data were collected. Identified population pharmacokinetic models were used to predict the amikacin concentrations in neonates. Predicted concentrations were compared against the observed concentrations. Differences between predicted and observed concentrations were quantified using statistical measures. The population pharmacokinetic model, which was able to predict the data well, is considered a suitable model for the study population. Dosing regimens were suggested for neonates using the pharmacometric simulation approach generated by the selected model. A total of 43 plasma samples were collected from 31 neonates. Twelve population pharmacokinetic models were found for amikacin in neonates. The predictive performance of the 12 studies was performed using clinical data. A two-compartment model reported by Illamola et al. predicted the amikacin concentrations better than other models. Illamola et al. reported creatinine clearance and body weight as the significant covariates impacting the pharmacokinetic parameters of amikacin. This model was able to predict the clinical data with 29.97% and 0.686 of relative median absolute prediction error and relative root mean square error, respectively, which is the best among the published models. The Illamola et al. model was selected as the final model to perform pharmacometric simulations for the subjects with different combinations of creatinine clearance and body weight. Dosage regimens were designed to attain target therapeutic concentrations for the virtual subjects and a nomogram was developed. The population pharmacokinetic model reported by the Illamola et al. model was selected as the final model to explain the clinical data with the lowest relative median absolute prediction error and relative root mean square error when compared with other models. An amikacin nomogram was developed for the neonates whose creatinine clearance and body weight ranged between 10 and 90 mL/min and between 2 and 4 kg, respectively. A developed nomogram can assist clinicians to design an optimal dosage regimen of amikacin for term neonates.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Amikacin is preferred in treating Gram-negative infections in neonates and it has a narrow therapeutic window. The population pharmacokinetic modeling approach can aid in designing optimal dosage regimens for amikacin in neonates. In this study, we attempted to identify the suitable population pharmacokinetic model from the published reports for the study population from an Indian setting.
METHODS
METHODS
Published population pharmacokinetic studies for amikacin in neonates were identified. Data on structural models and typical pharmacokinetic parameters were extracted from the studies. For the clinical study, neonates who met the inclusion criteria were enrolled in the study from the NICU, Kasturba Medical College, Manipal, during Jan 2020 to March 2022. Drug concentrations were estimated, and demographic and clinical data were collected. Identified population pharmacokinetic models were used to predict the amikacin concentrations in neonates. Predicted concentrations were compared against the observed concentrations. Differences between predicted and observed concentrations were quantified using statistical measures. The population pharmacokinetic model, which was able to predict the data well, is considered a suitable model for the study population. Dosing regimens were suggested for neonates using the pharmacometric simulation approach generated by the selected model.
RESULTS
RESULTS
A total of 43 plasma samples were collected from 31 neonates. Twelve population pharmacokinetic models were found for amikacin in neonates. The predictive performance of the 12 studies was performed using clinical data. A two-compartment model reported by Illamola et al. predicted the amikacin concentrations better than other models. Illamola et al. reported creatinine clearance and body weight as the significant covariates impacting the pharmacokinetic parameters of amikacin. This model was able to predict the clinical data with 29.97% and 0.686 of relative median absolute prediction error and relative root mean square error, respectively, which is the best among the published models. The Illamola et al. model was selected as the final model to perform pharmacometric simulations for the subjects with different combinations of creatinine clearance and body weight. Dosage regimens were designed to attain target therapeutic concentrations for the virtual subjects and a nomogram was developed.
CONCLUSIONS
CONCLUSIONS
The population pharmacokinetic model reported by the Illamola et al. model was selected as the final model to explain the clinical data with the lowest relative median absolute prediction error and relative root mean square error when compared with other models. An amikacin nomogram was developed for the neonates whose creatinine clearance and body weight ranged between 10 and 90 mL/min and between 2 and 4 kg, respectively. A developed nomogram can assist clinicians to design an optimal dosage regimen of amikacin for term neonates.
Identifiants
pubmed: 36943583
doi: 10.1007/s40272-023-00564-z
pii: 10.1007/s40272-023-00564-z
pmc: PMC10097735
doi:
Substances chimiques
Amikacin
84319SGC3C
Anti-Bacterial Agents
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-375Subventions
Organisme : Indian Council of Medical Research
ID : 5/7/1694/CH/Adhoc/RBMCH-2020
Informations de copyright
© 2023. The Author(s).
Références
Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012;73(1):27–36.
doi: 10.1111/j.1365-2125.2011.04080.x
pubmed: 21831196
pmcid: 3248253
Garraffo R, Drugeon HB, Dellamonica P, Bernard E, Lapalus P. Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob Agents Chemother. 1990;34(4):614–21.
doi: 10.1128/AAC.34.4.614
pubmed: 2111658
pmcid: 171653
Radigan EA, Gilchrist NA, Miller MA. Management of aminoglycosides in the intensive care unit. J Intensive Care Med. 2010;25(6):327–42.
doi: 10.1177/0885066610377968
pubmed: 20837630
Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol. 2009;65(7):705–13.
doi: 10.1007/s00228-009-0637-4
pubmed: 19305985
Kato H, Hagihara M, Hirai J, Sakanashi D, Suematsu H, Nishiyama N, et al. Evaluation of amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen. Drugs R D. 2017;17(1):177–87.
doi: 10.1007/s40268-016-0165-5
pubmed: 28063020
pmcid: 5318333
Alqahtani S, Abouelkheir M, Alsultan A, Elsharawy Y, Alkoraishi A, Osman R, et al. Optimizing amikacin dosage in pediatrics based on population pharmacokinetic/pharmacodynamic modeling. Paediatr Drugs. 2018;20(3):265–72.
doi: 10.1007/s40272-018-0288-y
pubmed: 29569124
Germovsek E, Barker CI, Sharland M. What do I need to know about aminoglycoside antibiotics? Arch Dis Child Educ Pract Ed. 2017;102(2):89–93.
doi: 10.1136/archdischild-2015-309069
pubmed: 27506599
Coppini R, Simons SHP, Mugelli A, Allegaert K. Clinical research in neonates and infants: challenges and perspectives. Pharmacol Res. 2016;108:80–7.
doi: 10.1016/j.phrs.2016.04.025
pubmed: 27142783
Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol. 1991;32(6):669–70.
pubmed: 1768557
pmcid: 1368544
Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometr Syst Pharmacol. 2012;1(9): e6.
doi: 10.1038/psp.2012.4
Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004;38(10):1702–6.
doi: 10.1345/aph.1D374
pubmed: 15328391
Allegaert K, Anderson BJ, Cossey V, Holford NH. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol. 2006;61(1):39–48.
doi: 10.1111/j.1365-2125.2005.02530.x
pubmed: 16390350
pmcid: 1884978
Allegaert K, Scheers I, Cossey V, Anderson BJ. Covariates of amikacin clearance in neonates: the impact of postnatal age on predictability. Drug Metab Lett. 2008;2(4):286–9.
doi: 10.2174/187231208786734157
pubmed: 19356107
Bleyzac N, Varnier V, Labaune JM, Corvaisier S, Maire P, Jelliffe RW, et al. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Eur J Clin Pharmacol. 2001;57(6–7):499–504.
pubmed: 11699615
Botha JH, du Preez MJ, Miller R, Adhikari M. Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models. Eur J Clin Pharmacol. 1998;53(5):337–41.
doi: 10.1007/s002280050389
pubmed: 9516033
Cristea S, Smits A, Kulo A, Knibbe CAJ, van Weissenbruch M, Krekels EHJ, et al. Amikacin pharmacokinetics to optimize dosing in neonates with perinatal asphyxia treated with hypothermia. Antimicrob Agents Chemother. 2017;61(12):e01282-e1317.
doi: 10.1128/AAC.01282-17
pubmed: 28993332
pmcid: 5700363
De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51(2):105–17.
doi: 10.2165/11595640-000000000-00000
pubmed: 22229883
Illamola SM, Colom H, van Hasselt JG. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Br J Clin Pharmacol. 2016;82(3):793–805.
doi: 10.1111/bcp.13016
pubmed: 27198625
pmcid: 5338126
Smits A, De Cock RF, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CA. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59(10):6344–51.
doi: 10.1128/AAC.01157-15
pubmed: 26248375
pmcid: 4576045
Wang J, Liang WQ, Wu JJ, Pan CM. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method. Acta Pharmacol Sin. 2000;21(10):954–60.
pubmed: 11501052
Amponsah SK, Adjei GO, Enweronu-Laryea C, Bugyei KA, Hadji-Popovski K, Kurtzhals JAL, et al. Population pharmacokinetic characteristics of amikacin in suspected cases of neonatal sepsis in a low-resource African setting: a prospective nonrandomized single-site study. Curr Ther Res Clin Exp. 2017;84:e1-6.
doi: 10.1016/j.curtheres.2017.01.001
pubmed: 28761582
pmcid: 5522970
Caceres Guido P, Travaglianti M, Castro G, Licciardone N, Ferreyra O, Bramuglia G, et al. Population pharmacokinetics of amikacin in neonatal intensive care unit patients. Aust Med J. 2017;10(02):140–4
Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr. 1984;104(6):849–54.
doi: 10.1016/S0022-3476(84)80479-5
pubmed: 6726515
Matcha S, Chaudhari BB, Mallayasamy S, Lewis LE, Moorkoth S. Ion-pairing reagent-free hydrophilic interaction LC-MS/MS method for therapeutic drug monitoring of amikacin in neonates. J Appl Pharm Sci. 2023;13(2):029–38.
Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503–12.
doi: 10.1007/BF01060893
pubmed: 7310648
Rackauckas C, Ma Y, Noack A, Dixit V, Mogensen PK, Elrod C, et al. Accelerated predictive healthcare analytics with pumas, a high performance pharmaceutical modelling and simulation platform. BioRxiv. 2022;1:1–23.
Micromedex. Amikacin: in depth answers. Greenwood Village: IBM Corporation. 2021. www.micromedexsolutions.com . Accessed 15 Oct 2021.
Winter ME. Basic clinical pharmacokinetics. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2010.
Go H, Momoi N, Kashiwabara N, Haneda K, Chishiki M, Imamura T, et al. Neonatal and maternal serum creatinine levels during the early postnatal period in preterm and term infants. PLoS ONE. 2018;13(5): e0196721.
doi: 10.1371/journal.pone.0196721
pubmed: 29795567
pmcid: 5967735
Wang H, Sherwin C, Gobburu JVS, Ivaturi V. Population pharmacokinetic modeling of gentamicin in pediatrics. J Clin Pharmacol. 2019;59(12):1584–96.
doi: 10.1002/jcph.1479
pubmed: 31286535
Falcao MC, Okay Y, Ramos JL. Relationship between plasma creatinine concentration and glomerular filtration in preterm newborn infants. Rev Hosp Clin Fac Med Sao Paulo. 1999;54(4):121–6.
doi: 10.1590/S0041-87811999000400004
pubmed: 10779819
Sulemanji M, Vakili K. Neonatal renal physiology. Semin Pediatr Surg. 2013;22(4):195–8.
doi: 10.1053/j.sempedsurg.2013.10.008
pubmed: 24331094
Krzyzanski W, Smits A, Van Den Anker J, Allegaert K. Population model of serum creatinine as time-dependent covariate in neonates. AAPS J. 2021;23(4):86.
doi: 10.1208/s12248-021-00612-x
pubmed: 34142253